CN100525825C - 'Naoxinan' tablet in use for cardiovascular disease, cerebrovascular disease and preparation method - Google Patents
'Naoxinan' tablet in use for cardiovascular disease, cerebrovascular disease and preparation method Download PDFInfo
- Publication number
- CN100525825C CN100525825C CNB2006100669177A CN200610066917A CN100525825C CN 100525825 C CN100525825 C CN 100525825C CN B2006100669177 A CNB2006100669177 A CN B2006100669177A CN 200610066917 A CN200610066917 A CN 200610066917A CN 100525825 C CN100525825 C CN 100525825C
- Authority
- CN
- China
- Prior art keywords
- radix
- parts
- fine powder
- add
- hours
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000026106 cerebrovascular disease Diseases 0.000 title claims abstract description 18
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title claims description 20
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 25
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 25
- 230000002526 effect on cardiovascular system Effects 0.000 claims abstract description 16
- 239000000463 material Substances 0.000 claims abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 43
- 239000000843 powder Substances 0.000 claims description 40
- 239000009636 Huang Qi Substances 0.000 claims description 39
- 241000756943 Codonopsis Species 0.000 claims description 27
- 238000002156 mixing Methods 0.000 claims description 26
- 244000153234 Hibiscus abelmoschus Species 0.000 claims description 24
- 239000000796 flavoring agent Substances 0.000 claims description 24
- 235000019634 flavors Nutrition 0.000 claims description 24
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims description 23
- 241000131808 Scolopendra Species 0.000 claims description 23
- 241000522620 Scorpio Species 0.000 claims description 23
- 239000009490 scorpio Substances 0.000 claims description 23
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 20
- 229920001353 Dextrin Polymers 0.000 claims description 17
- 239000004375 Dextrin Substances 0.000 claims description 17
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 17
- 235000019425 dextrin Nutrition 0.000 claims description 17
- 238000001035 drying Methods 0.000 claims description 17
- 239000008101 lactose Substances 0.000 claims description 17
- 210000004556 brain Anatomy 0.000 claims description 16
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 15
- 239000008187 granular material Substances 0.000 claims description 15
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 14
- 238000000576 coating method Methods 0.000 claims description 12
- 239000000706 filtrate Substances 0.000 claims description 12
- 241000489492 Arisaema Species 0.000 claims description 11
- 239000002671 adjuvant Substances 0.000 claims description 11
- 210000000941 bile Anatomy 0.000 claims description 11
- 239000011248 coating agent Substances 0.000 claims description 11
- 210000000582 semen Anatomy 0.000 claims description 11
- 229920002472 Starch Polymers 0.000 claims description 10
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 10
- 235000019359 magnesium stearate Nutrition 0.000 claims description 10
- 239000008107 starch Substances 0.000 claims description 10
- 235000019698 starch Nutrition 0.000 claims description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 5
- 229930195725 Mannitol Natural products 0.000 claims description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 5
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 5
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 5
- 239000000594 mannitol Substances 0.000 claims description 5
- 235000010355 mannitol Nutrition 0.000 claims description 5
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 5
- 239000000741 silica gel Substances 0.000 claims description 5
- 229910002027 silica gel Inorganic materials 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- 229920000881 Modified starch Polymers 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 235000014375 Curcuma Nutrition 0.000 claims description 2
- 244000164439 Curcuma angustifolia Species 0.000 claims description 2
- 241000219780 Pueraria Species 0.000 claims description 2
- 241000545442 Radix Species 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 15
- 238000000034 method Methods 0.000 abstract description 10
- 230000008569 process Effects 0.000 abstract description 4
- 235000015655 Crocus sativus Nutrition 0.000 abstract 1
- 244000124209 Crocus sativus Species 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 235000013974 saffron Nutrition 0.000 abstract 1
- 239000004248 saffron Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 22
- 239000008280 blood Substances 0.000 description 22
- 230000000694 effects Effects 0.000 description 13
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 12
- 239000012567 medical material Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 9
- 230000017531 blood circulation Effects 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 238000009740 moulding (composite fabrication) Methods 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- 235000013339 cereals Nutrition 0.000 description 7
- 239000000945 filler Substances 0.000 description 7
- 238000005303 weighing Methods 0.000 description 7
- 239000002775 capsule Substances 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 235000013312 flour Nutrition 0.000 description 5
- 208000007536 Thrombosis Diseases 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 229950005770 hyprolose Drugs 0.000 description 4
- 230000000302 ischemic effect Effects 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 206010002383 Angina Pectoris Diseases 0.000 description 3
- 206010019468 Hemiplegia Diseases 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 230000009747 swallowing Effects 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010061876 Obstruction Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 235000019606 astringent taste Nutrition 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000003727 cerebral blood flow Effects 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- JLTCWSBVQSZVLT-CDIPANDDSA-N (2s)-n-[(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosan Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1.C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 JLTCWSBVQSZVLT-CDIPANDDSA-N 0.000 description 1
- 206010001526 Air embolism Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 208000035985 Body Odor Diseases 0.000 description 1
- 208000002381 Brain Hypoxia Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 206010055000 Bromhidrosis Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 244000182067 Fraxinus ornus Species 0.000 description 1
- 235000002917 Fraxinus ornus Nutrition 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 241001676635 Lepidorhombus whiffiagonis Species 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000005320 Posterior Pituitary Hormones Human genes 0.000 description 1
- 108010070873 Posterior Pituitary Hormones Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000014604 Specific Language disease Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- GUBGYTABKSRVRQ-ASMJPISFSA-N alpha-maltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-ASMJPISFSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 230000003257 anti-anginal effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004781 brain capillary Anatomy 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 239000002021 butanolic extract Substances 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 238000002309 gasification Methods 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000013081 microcrystal Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 108700026460 mouse core Proteins 0.000 description 1
- 208000010553 multiple abscesses Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000011020 pilot scale process Methods 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- BUKHSQBUKZIMLB-UHFFFAOYSA-L potassium;sodium;dichloride Chemical compound [Na+].[Cl-].[Cl-].[K+] BUKHSQBUKZIMLB-UHFFFAOYSA-L 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006100669177A CN100525825C (en) | 2006-04-03 | 2006-04-03 | 'Naoxinan' tablet in use for cardiovascular disease, cerebrovascular disease and preparation method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006100669177A CN100525825C (en) | 2006-04-03 | 2006-04-03 | 'Naoxinan' tablet in use for cardiovascular disease, cerebrovascular disease and preparation method |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101049462A CN101049462A (en) | 2007-10-10 |
CN100525825C true CN100525825C (en) | 2009-08-12 |
Family
ID=38781198
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2006100669177A Active CN100525825C (en) | 2006-04-03 | 2006-04-03 | 'Naoxinan' tablet in use for cardiovascular disease, cerebrovascular disease and preparation method |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100525825C (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102293822A (en) * | 2010-06-28 | 2011-12-28 | 天津天士力制药股份有限公司 | Application of traditional Chinese medicine composition in preparation of medicines used for reducing occurrence of cardiovascular events after acute myocardial infarction |
CN103083473A (en) * | 2011-11-08 | 2013-05-08 | 谢朝云 | Medicament for treating heart disease and preparation method thereof |
CN102940668B (en) * | 2012-10-31 | 2014-05-07 | 成都医路康医学技术服务有限公司 | Medicine composition for treating cardia-cerebrovascular diseases |
CN103041292B (en) * | 2012-11-29 | 2014-04-09 | 宁国市中医肿瘤医院 | Traditional Chinese medicine for treating apoplexy |
CN104940808A (en) * | 2015-05-31 | 2015-09-30 | 陆仲新 | Traditional Chinese medicine for treatment of blood stasis and internal stagnation cerebral arteriosclerosis and preparation method thereof |
CN104984139A (en) * | 2015-07-28 | 2015-10-21 | 王雄 | Traditional Chinese medicine composition for treating three-hypers |
CN105381064A (en) * | 2015-11-16 | 2016-03-09 | 宁国仙霞骨伤医院 | Traditional Chinese medicine composition for treating cerebral hemorrhage |
CN105412850A (en) * | 2016-01-26 | 2016-03-23 | 青岛大学附属医院 | Medicine composition for treating cardiovascular and cerebrovascular diseases and preparation method of medicine composition |
-
2006
- 2006-04-03 CN CNB2006100669177A patent/CN100525825C/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN101049462A (en) | 2007-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100525825C (en) | 'Naoxinan' tablet in use for cardiovascular disease, cerebrovascular disease and preparation method | |
CN102512521A (en) | Traditional Chinese medicine composition for treating apoplexy sequela | |
CN103520572A (en) | Traditional Chinese composition used for treating atopic dermatitis as well as preparation method of composition | |
CN103055239B (en) | Traditional Chinese medicine for beautifying face and removing freckles and preparation method thereof | |
CN102973799B (en) | Pill used for post-anesthesia nerve injury | |
CN103520694A (en) | Traditional Chinese medicine composition capable of treating chronic obstructive pulmonary disease in stabilization period and preparation method of composition | |
CN100569220C (en) | A kind of menstruation regulation and macula removal tablet that is used for gynecological and preparation method thereof | |
CN108142986A (en) | A kind of Chinese herbal medicine composite extract, preparation method and its application in cigarette | |
CN101417070A (en) | Pharmaceutical composition for treating constipation and preparation method thereof | |
CN101049440B (en) | Preparation of Chinese traditional medicine in use for diabetes, and preparation method | |
CN102078543A (en) | Traditional Chinese medicine preparation for treating gout and preparation method thereof | |
CN102085344B (en) | Aplotaxis carminative sustained-release preparation and preparation method thereof | |
CN103990103A (en) | Medicine for local anaesthesia and preparation method of medicine | |
CN103933419A (en) | Traditional Chinese medicine for treating dermatophytosis | |
CN101884671B (en) | Food therapy preparation for preventing and treating asthma based on theories of preventive treatment of disease and medicine food homology | |
CN103735973A (en) | Traditional Chinese medicine composition for improving memory and preparation method thereof | |
CN105457005A (en) | Traditional Chinese medicine composition used for treating bronchial asthma and preparation method thereof | |
CN1853670B (en) | Coronary heart Danshen root micropellets and preparation thereof | |
CN102988938A (en) | Traditional Chinese medicine composition for treating arrhythmia or atrial fibrillation and preparation method thereof | |
CN104208398A (en) | Medicine for treating coronary heat disease, angina and arrhythmia and preparation method thereof | |
CN109999076A (en) | It is a kind of adjust reverse cholesterol transport Chinese medicine composition and its application | |
CN106138795B (en) | Traditional Chinese medicine composition for treating premature beat and preparation method thereof | |
CN102526470B (en) | Medicinal composition for treating primary hypertension | |
CN109223867A (en) | The relieving cough and reducing sputum Chinese medicine composition and its preparation method and application relievingd asthma | |
CN103285193A (en) | Lung-tonifying capsule for treating lung-distension caused by qi deficiency of lung and kidney and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Bayer Healthcare LLC Assignor: Beijing Yinkeruisi Biological Products Research Institute Contract fulfillment period: 2009.9.15 to 2014.9.14 contract change Contract record no.: 2009110000210 Denomination of invention: 'Naoxinan' tablet in use for cardiovascular disease, cerebrovascular disease and preparation method Granted publication date: 20090812 License type: Exclusive license Record date: 2009.9.23 |
|
LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2009.9.15 TO 2014.9.14; CHANGE OF CONTRACT Name of requester: BAYER HEALTHCARE CO. Effective date: 20090923 |
|
ASS | Succession or assignment of patent right |
Owner name: ZHUHAI BAODE RUNSHENG HEALTH TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: BEIJING YINKERUISI BIOLOGICAL PRODUCTS RESEARCH INSTITUTE Effective date: 20150319 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100088 XICHENG, BEIJING TO: 519040 ZHUHAI, GUANGDONG PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20150319 Address after: 519040 Guangdong city of Zhuhai province Jinwan District Sanzao Town Airport Road No. 288 building four floor F area B Patentee after: Zhuhai Bao Derun Health Technology Co., Ltd. Address before: 100088 Beijing city Xicheng District, New Street No. 2 Tiancheng Technology building block B room 3003 Patentee before: Beijing Yinkeruisi Biological Products Research Institute |
|
TR01 | Transfer of patent right |
Effective date of registration: 20161223 Address after: Beijing city Changping District town Beiqijia Hongfu building room 1009 Patentee after: Beijing Ying Kerui Biological Medicine Research Co Ltd Address before: 519040 Guangdong city of Zhuhai province Jinwan District Sanzao Town Airport Road No. 288 building four floor F area B Patentee before: Zhuhai Bao Derun Health Technology Co., Ltd. |
|
TR01 | Transfer of patent right |